Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Misgav

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Harefuah|July 29, 2000
[Upper extremity deep vein thrombosis]M Misgav, S Berliner
Harefuah|July 27, 2000
[Atrial septal aneurysm as a possible cause of cardiac embolism]C Perry, M Misgav, S Berliner
Harefuah|September 9, 2000
[A new mutation in the prothrombin gene (G20210A) and the risk for venous and arterial thromboembolism]M Misgav, A Eldor, S Berliner
Harefuah|August 3, 2001
[Thrombotic thrombocytopenic purpura--new insights in the pathogenesis, diagnosis and modern therapy]M Misgav, S Berliner, A Eldor
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|August 11, 2000
Fatal pulmonary artery thrombosis in a patient with Behçet's disease, activated protein C resistance and hyperhomocystinemiaM Misgav, Y Goldberg, D Zeltser, et al.
Vox Sanguinis|July 21, 2004
Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleedingA Mayo, M Misgav, Y Kluger, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 30, 2011
Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia AU Martinowitz, J Bjerre, B Brand, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 9, 2011
Recombinant factor concentrates may increase inhibitor development: a single centre cohort studyT Strauss, A Lubetsky, B Ravid, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 11, 2015
Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trialM Ozelo, M Misgav, F Abdul Karim, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 3, 2014
Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trialsE Santagostino, S R Lentz, M Misgav, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Harefuah|July 29, 2000
[Upper extremity deep vein thrombosis]M Misgav, S Berliner
Harefuah|July 27, 2000
[Atrial septal aneurysm as a possible cause of cardiac embolism]C Perry, M Misgav, S Berliner
Harefuah|September 9, 2000
[A new mutation in the prothrombin gene (G20210A) and the risk for venous and arterial thromboembolism]M Misgav, A Eldor, S Berliner
Harefuah|August 3, 2001
[Thrombotic thrombocytopenic purpura--new insights in the pathogenesis, diagnosis and modern therapy]M Misgav, S Berliner, A Eldor
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|August 11, 2000
Fatal pulmonary artery thrombosis in a patient with Behçet's disease, activated protein C resistance and hyperhomocystinemiaM Misgav, Y Goldberg, D Zeltser, et al.
Vox Sanguinis|July 21, 2004
Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleedingA Mayo, M Misgav, Y Kluger, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 30, 2011
Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia AU Martinowitz, J Bjerre, B Brand, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 9, 2011
Recombinant factor concentrates may increase inhibitor development: a single centre cohort studyT Strauss, A Lubetsky, B Ravid, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 11, 2015
Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trialM Ozelo, M Misgav, F Abdul Karim, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 3, 2014
Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trialsE Santagostino, S R Lentz, M Misgav, et al.
Pageof 2